The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Based on a post hoc analysis, fewer required respiratory interventions
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
States have an important role in ensuring food safety and healthy food practices.
Subscribe To Our Newsletter & Stay Updated
